AI/ML‐Driven DPP‐4 Inhibitor Predictor (d4p_v1) for Enhanced Type 2 Diabetes Mellitus Management: Insights Into Chemical Space, Fingerprints, and Electrostatic Potential Maps
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.70106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Anu Manhas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, School of Energy Technology, Pandit Deendayal Energy University, Gandhinagar, India. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Dipeptidyl Peptidase 4. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..
Themen: Diabetes mellitus
Abstract (Originalsprache)
Dipeptidyl peptidase‐4 inhibitors (DPP‐4i) represent a relatively new class of oral antidiabetic drugs. This study focuses on: (a) identifying favourable and unfavourable fingerprints governing DPP‐4 inhibition using fragment‐based analysis, (b) validating key fingerprints through HOMO–LUMO gap analysis and electrostatic potential (ESP) maps, and (c) developing AI/ML‐driven DPP‐4 predictor, an online cheminformatics tool for efficient DPP‐4i screening using a trained, validated AI/ML model. The fragment‐based QSAR model finds key substructures linked to potent DPP‐4 inhibition, including 2‐cyanopyrrolidine, 3‐amino tetrahydropyran, and difluoro phenyl groups. D0010 (3‐aminotetrahydropyran fingerprint G10) is the most reactive, while D0094 (difluorophenyl fingerprint G14) is the most stable, with D0012 and D0013 (2‐cyanopyrrolidine fingerprints G1, G5) offering a balance between stability and reactivity. In addition, the d4p_v1 tool ( https://github.com/Amincheminfom/d4p_v1 ) reliably distinguishes active and inactive DPP‐4i using molecular descriptors derived from input SMILES strings. Therefore, this study not only revealed the chemical space of DPP‐4i but also opened up a horizon in developing novel potent DPP‐4i for the management of type 2 diabetes mellitus (T2DM) in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, School of Energy Technology, Pandit Deendayal Energy University, Gandhinagar, India.
- Department of Pharmaceutical Technology, JIS University, Kolkata, West Bengal, India.
- Department of Pharmacy, University of Salerno, Fisciano, SA, Italy.
ORCID-Profile: Anu Manhas, Sk Abdul Amin
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Manhas, A., Dutta, R., Piotto, S., & Amin, S. A. (2025). AI/ML‐Driven DPP‐4 Inhibitor Predictor (d4p_v1) for Enhanced Type 2 Diabetes Mellitus Management: Insights Into Chemical Space, Fingerprints, and Electrostatic Potential Maps. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70106
Vancouver
Manhas A, Dutta R, Piotto S, Amin SA. AI/ML‐Driven DPP‐4 Inhibitor Predictor (d4p_v1) for Enhanced Type 2 Diabetes Mellitus Management: Insights Into Chemical Space, Fingerprints, and Electrostatic Potential Maps. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70106
BibTeX
@article{Manhas2025,
author = {Manhas, Anu and Dutta, Ritam and Piotto, Stefano and Amin, Sk Abdul},
title = {AI/ML‐Driven DPP‐4 Inhibitor Predictor (d4p_v1) for Enhanced Type 2 Diabetes Mellitus Management: Insights Into Chemical Space, Fingerprints, and Electrostatic Potential Maps},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.70106}
}
EUVIMED